25 related articles for article (PubMed ID: 15457125)
1. Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay.
Ling ZQ; Qi CJ; Lu XX; Qian LJ; Gu LH; Zheng ZG; Zhao Q; Wang S; Fang XH; Yang ZX; Yin J; Mao WM
Acta Pharmacol Sin; 2012 Mar; 33(3):401-6. PubMed ID: 22286916
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II.
Mistry P; Stewart AJ; Dangerfield W; Baker M; Liddle C; Bootle D; Kofler B; Laurie D; Denny WA; Baguley B; Charlton PA
Anticancer Drugs; 2002 Jan; 13(1):15-28. PubMed ID: 11914637
[TBL] [Abstract][Full Text] [Related]
3. The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples.
Di Nicolantonio F; Knight LA; Whitehouse PA; Mercer SJ; Sharma S; Charlton PA; Norris D; Cree IA
Mol Cancer Ther; 2004 Dec; 3(12):1631-7. PubMed ID: 15634657
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo reversal of chemoresistance by tariquidar (XR9576).
Di Nicolantonio F; Knight LA; Glaysher S; Whitehouse PA; Mercer SJ; Sharma S; Mills L; Prin A; Johnson P; Charlton PA; Norris D; Cree IA
Anticancer Drugs; 2004 Oct; 15(9):861-9. PubMed ID: 15457126
[TBL] [Abstract][Full Text] [Related]
5. Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Knight LA; Conroy M; Fernando A; Polak M; Kurbacher CM; Cree IA
Anticancer Drugs; 2005 Oct; 16(9):969-76. PubMed ID: 16162973
[TBL] [Abstract][Full Text] [Related]
6. Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases.
Jobson AG; Willmore E; Tilby MJ; Mistry P; Charlton P; Austin CA
Cancer Chemother Pharmacol; 2009 Apr; 63(5):889-901. PubMed ID: 18679685
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors.
Di Nicolantonio F; Knight LA; Di Palma S; Sharma S; Whitehouse PA; Mercer SJ; Charlton PA; Norris D; Cree IA
Anticancer Drugs; 2004 Oct; 15(9):849-60. PubMed ID: 15457125
[TBL] [Abstract][Full Text] [Related]
8. ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
Kurbacher CM; Grecu OM; Stier U; Gilster TJ; Janát MM; Untch M; Konecny G; Bruckner HW; Cree IA
Recent Results Cancer Res; 2003; 161():221-30. PubMed ID: 12528810
[TBL] [Abstract][Full Text] [Related]
9. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
Minagawa Y; Kigawa J; Itamochi H; Terakawa N
Hum Cell; 2001 Sep; 14(3):237-43. PubMed ID: 11774743
[TBL] [Abstract][Full Text] [Related]
10. Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.
Goa KL; Faulds D
Drugs Aging; 1994 Sep; 5(3):200-34. PubMed ID: 7803948
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel in combination chemotherapy for metastatic breast cancer.
Khayat D; Antoine E
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
